AGI-1067 [succinobucol] as a novel antidiabetic agent evaluation study
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Mar 2010
At a glance
- Drugs Succinobucol (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms ANDES
- Sponsors AtheroGenics
- 10 Jun 2017 Biomarkers information updated
- 01 Aug 2008 Primary endpoint achieved, as reported in a AtherGenics media release.
- 04 Jun 2008 Final results are expected in the third quarter of 2008.